Agenerase (Amprenavir) - Summary

AGENERASE SUMMARY

AGENERASE®
(amprenavir)
Capsules
PATIENT INFORMATION INCLUDED

AGENERASE (amprenavir) is an inhibitor of the human immunodeficiency virus (HIV) protease.

AGENERASE (amprenavir) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

The following points should be considered when initiating therapy with AGENERASE:

In a study of NRTI-experienced, protease inhibitor-naive patients, AGENERASE was found to be significantly less effective than indinavir.

Mild to moderate gastrointestinal adverse events led to discontinuation of AGENERASE primarily during the first 12 weeks of therapy (ADVERSE REACTIONS).

There are no data on response to therapy with AGENERASE in protease inhibitor-experienced patients.

See all Agenerase indications & dosage >>

AGENERASE NEWS HIGHLIGHTS

Media Articles Related to Agenerase (Amprenavir)

fosamprenavir-oral, Lexiva
Source: MedicineNet amprenavir Specialty [2005.03.02]

First days after HIV infection may hold vaccine key (Reuters)
Source: Y! Health HIV & AIDS News [2008.12.01]

Herpes Suppression May Not Prevent HIV Infection
Source: MedicineNet Genital Herpes In Women Specialty [2008.06.20]

Newly Reported HIV Cases On The Rise In Europe
Source: Health News from Medical News Today [2008.12.01]

GPs In For The Long Haul For Our Hiv/ Aids Patients - Royal Australian College Of General Practitioners
Source: HIV / AIDS News From Medical News Today [2008.12.01]

more >>

Published Studies Related to Agenerase (Amprenavir)

Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir. [2007.06.19]

Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir. [2006.08]

Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV. [2006.04]

Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. [2006.03]

Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. [2005.01.28]

more >>

Clinical Trials Related to Agenerase (Amprenavir)

A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir [Completed]

A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients [Completed]

An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen [Completed]

Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients [Active, not recruiting]

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients [Completed]

more >>